Skip to main content
. Author manuscript; available in PMC: 2011 Aug 16.
Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 24;34(6):913–923. doi: 10.1016/j.pnpbp.2010.04.016

Figure 4.

Figure 4

Effects of chronic DMI treatment (7.5 mg/kg/day) during CUS on AST performance in the tasks tested prior to drug microinjections into mPFC. In vehicle-treated rats, CUS produced a significant performance deficit on the first reversal task (R1), manifest as significantly higher number of trials required to reach criterion (*p < 0.001 compared to vehicle-treated unstressed control rats on the same task). This effect was prevented by chronic treatment with DMI (+p<0.001 compared to vehicle-treated rats subjected to CUS on the same task; data expressed as mean ± S.E.M.; n = 11–16/group).